Summary:
This is a controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and adult subjects with atopic dermatitis.
Criteria:- Male and female subjects ages 2 to 18 with a clinical diagnosis of AD
- Atopic dermatitis present for at least 6 months
- Female subjects of childbearing potential who are engaging in sexual activity that could lead to pregnancy should use acceptable birth control methods
- Must not be pregnant
- Subject, subject's parent, or legal representative must be capable of giving written informed consent/assent
Qualified Participants May Receive:
$75 compensation for every visit, treatment, & labs